Zobrazeno 1 - 10
of 214
pro vyhledávání: ''
Publikováno v:
Clinical and Vaccine Immunology. 23:884-887
Patients with end-stage renal disease (ESRD) and on dialysis are at increased risk of pneumococcal disease. We evaluated the immunogenicity of the 13-valent pneumococcal conjugate vaccine (PCV13) in this population. Eligible patients with ESRD and on
Autor:
Detlef Grunert, Devayani Kolhe, Juan C. Tejedor, Yaela Baine, Jerzy Brzostek, Marie Van der Wielen, Ryszard Konior
Publikováno v:
Clinical and Vaccine Immunology : CVI
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
We evaluated antibody persistence in children up to 5 years after administration of a combined Haemophilus influenzae type b (Hib)- Neisseria meningitidis serogroup C (MenC)-tetanus toxoid (TT) conjugate vaccine coadministered with a pneumococcal con
Publikováno v:
Clinical and Vaccine Immunology. 23:417-426
Cryopreserved peripheral blood mononuclear cells (PBMCs) are widely used in studies of dengue. In this disease, elevated frequency of apoptotic PBMCs has been described, and molecules such as soluble tumor necrosis factor (TNF)-related apoptosis-indu
Publikováno v:
Clinical and Vaccine Immunology. 23:162-167
The efficacy of the serotype 3 (ST3) pneumococcal conjugate vaccine (PCV) remains unclear. While the synthesis of capsular polysaccharide (CPS) of most serotypes is wzy dependent, the strains of two serotypes, 3 and 37, synthesize CPS by the synthase
Autor:
Mark T. Esser, Jared Pache, Li Yu, Stacie L. Lambert, Cindy Shambaugh, Sarieh Azshirvani, Fengrong Zuo
Publikováno v:
Clinical and Vaccine Immunology : CVI
Neutralizing antibodies specific for respiratory syncytial virus (RSV) represent a major protective mechanism against RSV infection, as demonstrated by the efficacy of the immune-prophylactic monoclonal antibody palivizumab in preventing RSV-associat
Autor:
Su-Jin Park, Taeyeon Kim, Chanhee Chae, Kyuhyung Choi, Changhoon Park, Jiwoon Jeong, Ikjae Kang
Publikováno v:
Clinical and Vaccine Immunology. 22:631-640
The objective of the present study was to compare the efficacy of two commercial type 1 porcine reproductive and respiratory syndrome virus (PRRSV) modified live vaccines against heterologous type 1 and type 2 PRRSV challenge in growing pigs. Vaccina
Autor:
Eeva Auvinen, Klaus Hedman, Lea Hedman, Piotr Kardas, Mohammadreza Sadeghi, Tingting Chen, Fabian H. Weissbach, Hans H. Hirsch
Publikováno v:
Clinical and Vaccine Immunology. 21:1581-1588
JC polyomavirus (JCPyV) can cause progressive multifocal leukoencephalopathy (PML), a debilitating, often fatal brain disease in immunocompromised patients. JCPyV-seropositive multiple sclerosis (MS) patients treated with natalizumab have a 2- to 10-
Autor:
Christopher M. Waters, Andrea Amalfitano, Benjamin J. Koestler, Sarah Godbehere, Yasser A. Aldhamen, David P W Rastall, Sergey S. Seregin
Publikováno v:
Clinical and Vaccine Immunology. 21:1550-1559
The bacterial second messenger cyclic di-GMP (c-di-GMP) stimulates inflammation by initiating innate immune cell recruitment and triggering the release of proinflammatory cytokines and chemokines. These properties make c-di-GMP a promising candidate
Autor:
David Greenberg, Noga Givon-Lavi, Alejandra Gurtman, James Trammel, Ron Dagan, Christine Juergens, Daniel A. Scott, Scott Patterson, David A. Cooper, William C. Gruber
Publikováno v:
Clinical and Vaccine Immunology. 21:1277-1281
In a randomized double-blind trial in healthy Israeli infants in Israel who received the 13-valent or 7-valent pneumococcal conjugate vaccine (PCV13 or PCV7, respectively) at 2, 4, 6, and 12 months, PCV13 significantly reduced nasopharyngeal (NP) col
Autor:
Angela Fuery, Anthony D. Keil, Peter Richmond, B. Jan Jones, Lea-Ann S. Kirkham, Shyan Vijayasekaran, Guicheng Zhang, Selma P. Wiertsema, Ruth B. Thornton, Karli J. Corscadden, Harvey Coates
Publikováno v:
Clinical and Vaccine Immunology : CVI
Indigenous populations experience high rates of otitis media (OM), with increased chronicity and severity, compared to those experienced by their nonindigenous counterparts. Data on immune responses to otopathogenic bacteria in these high-risk popula